Motley Fool: Amarin: Keep Your Dry Powder Ready

Even though I’m an unabashed bull for Amarin (NASDAQ:AMRN), I’ve never bought a single share of this promising biotech stock. The reason is that I’ve been waiting for a specific buying opportunity. Namely, the company’s upcoming advisory committee meeting for…

Advertisements

Motley Fool: Ionis Pharmaceuticals Looks to Partners to Pay the Bills

Ionis Pharmaceuticals (NASDAQ:IONS) continues to rack up royalties from its spinal muscular atrophy drug Spinraza while the rest of its extensive pipeline basically pays the rest of the biotech’s bills. Ionis Pharmaceuticals results: The raw numbers Metric Q2 2019 Q2…

Motley Fool: 3 Top Dividend Stocks to Buy Right Now

If you’re in search of dividend stocks to buy today, then look no further than global drug giant Novartis (NYSE:NVS), U.S. telecom leader Verizon (NYSE:VZ), and packaged food icon General Mills (NYSE:GIS). Although these dividend stocks’ stories are different, the…

Motley Fool: Is Now a Good Time to Buy Tilray Inc.?

Momentum is building for marijuana stocks ahead of the opening of Canada’s recreational cannabis market in October, and Tilray Inc. (NASDAQ:TLRY) is among the industry’s biggest recent winners. Tilray’s shares have almost doubled this month because of growing optimism that…